All News
Anti-Sclerostin Drug Prevents Vertebral Fractures in Post-Menopausal Osteoporosis
Romosozumab is being developed as a novel therapy for osteoporosis. It is a monoclonal antibody that binds sclerostin, and has been shown to increase bone formation while decreasing bone resorption.
Read Article
FDA Approves New Amgen Biosimilar for Adalimumab
2016 has been a big year for biosimilars in rheumatology.
Read Article
FDA Approves Stelara for Crohn's Colitis
The anti-IL-12/IL-23 inhibitor, Stelara (ustekinumab) has been FDA approved for the treatment of psoriasis and psoriatic arthritis. In the last week, the EMA's CHMP has recommended that the drug also be approved for use in Crohn's disease.
Read Article
Restricting High Price Drugs - A Dangerous Trend?
Who makes billions in profits and millions in bonus monies? PBMs and insurers, thats who.
This week United Healthcare and Express Scripts announced new plans to restrict patient and prescriber access to popular, expensive, albeit FDA-approved, medications and biologics.
Who benefits, who loses?
Recognizing Arboviral Infections in Rheumatic Disease Patients.
What does sex have to do with it? Although the Zika virus infection is known to be sexually transmitted, the same cannot be claimed for Dengue or Chikungunya.
Read Article
Wearable Activity Trackers Don't Improve Weight Loss
JAMA has reported the results of a 24-month trial showing that obese individuals on a long-term healthy diet and exercise program do not have significantly more weight loss from using a wearable device that tracks their activity.
Read ArticleRheumNow Week in Review – 16 September 2016
A review of this week's news including the cost of opioid abuse, a RTX biosimilar, a new drug for scleroderma, a new shingles vaccine and a CPAP disappointment.
Read Article
CDC Reports 31 Million Older Americans Don't Get Adequate Exercise
The Sept.16th issue of MMWR reports that many Americans over age 50 are not getting sufficient exercise, thereby increasing their risk for falls, fractures and comorbidities, if not premature death. (Citation source http://buff.ly/2cPAcq9)
Read Article
DSB Reports and Updates - September 2016
Updates and journal articles on opioids, drug induced sarcoidosis, cancer and cancer recurrence risks with TNF inhibitors and biologics, and FDA labeling changes.
Read Article
Fibromyalgia - Should Internists Manage a Contested Illness?
The current issue of ACP Internist discusses the considerable dissent among the medical community about fibromyalgia (FM), its cause, diagnosis and care. This review addresses many concerns with input from well-known experts in rheumatology.
Read Article
CPAP Use Fails to Prevent CV Events in Sleep Apnea Patients
There are numerous health hazards associated with obstructive sleep apnea (OSA), including an increased risk of cardiovascular events.
Read Article
Lupus Patients at Higher Risk for Heart Failure
Although cardiovascular disease and complications have been well-described in patients with systemic lupus erythematosus (SLE), the association between SLE and heart failure (HF) remains undefined.
Read Article
The RheumNow Week in Review – 9 September 2016
Dr. Jack Cush reviews highlights from the past week on RheumNow.com, including IBD/TNFi and cancer risk, fracture nonunion, PMR worse in women, not treating asymptomatic hyperuricemia, and shingles followed by stroke.
Read Article
P. Gingivalis Antibodies Antedate Rheumatoid Arthritis Onset
Periodontal disease, gingivitis and Porphyromonas gingivalis have been linked to the pathogenesis of rheumatoid arthritis (RA) and the production of anti-citrullinated protein antibodies (ACPA).
Read Article
AMA Policy on Freebies and Meals Clarified
A recent JAMA Internal Medicine report on pharmaceutical-sponsored meals disclosed that a $20 meal provided by a drug company could yields 2-5 times more prescriptions. (Citation source http://buff.ly/2cd58i0)
Read Article
EMRs Causing Physician Burnout
Researchers suggest that the burden of EHRs could contribute to physician burnout. The findings of a time and motion study are published in Annals of Internal Medicine.
Read Article
RheumNow Week in Review – 2 September 2016
Dr. Jack Cush reviews highlights from this week in RheumNow:
Read Article
Cost of Osteoporosis Care in the USA
The 2010 NHANES study suggests that the overall prevalence of osteoporosis (OP) in the USA is ~10% or 10.2 million older adults (> 50 yrs) had osteoporosis.
Read Article
HMGB1 as a Biomarker for Polymyositis and Dermatomyositis
High mobility group box chromosomal protein 1 (HMGB1) is a DNA-binding protein that functions as a structural co-factor. HMGB1 is actively secreted by macrophage/monocytes via inflammatory stimuli and is elaborated during apoptosis.
Read Article
Zurampic Helps Allopurinol Non-Responders
Lesinurad (Zurampic) was approved earlier this year as adjunctive therapy to other urate-lowering therapies. It is a selective uric acid reabsorption inhibitor (URAT-1 inhibitor) designed to treat gout, and be used in combination with other xanthine oxidase inhibitors.
Read Article
